COMPANY

Cagent Vascular

HQ: Wayne, PA source · cagentvascular.com ↗

Keywords: cardiovascular cardiovascular disease Critical Limb Ischemia Peripheral Arterial Disease Peripheral Artery Disease Dysfunctional AV Fistula Dysfunctional AV Graft Arterio-venous Fistula Arteriovenous Graft Serranator Sonic Intravascular Lithotripsy (IVL) System Peripheral balloon angioplasty Serranator Serranator® Alto Serranator™ Alto PTA Serration Balloon Catheter

Location: Wayne, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$41.0MRaised (2 yrs)7Trials (company is sponsor)

Raises and deals from press releases

Raise Series D · $41M · announced Jul 15, 2026 Company release ↗
Source quote
- Jul 15, 2026 · Company release ↗
  “)--Cagent Vascular, Inc., a leader in endovascular technologies, today announced two milestones: the successful completion of first human-use cases with the SONIC Intravascular Lithotripsy (IVL) System and the closing of a $41 million Series D financing round”
Raise Series C · more than $30M · announced Feb 19, 2024 Company release ↗
Source quote
- Feb 19, 2024 · Company release ↗
  “Funds will be used to accelerate US market adoption and to expand the product portfolio of the first and only Serration Angioplasty Technology (Wayne, PA) Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M.”

Raises announced in these releases: $71M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jul 15, 2026 Raise Private equity round — Series D: $41M (total, as published), announced Jul 15, 2026. Source: company's own press page. source ↗ · Form D filed Jun 5, 2026 SEC Form D ↗
Jul 15, 2026 Raise Series D · $41M source ↗
Jan 22, 2025 Trial start —: Serranator POINT FORCE Registry source ↗
Oct 31, 2024 Trial start Not phased (device or behavioral study): Serrantor OCT Study source ↗
Feb 19, 2024 Raise Series C · more than $30M source ↗
Nov 15, 2021 Trial start Not phased (device or behavioral study): Serranator Recoil Study source ↗
Dec 17, 2019 Trial start Not phased (device or behavioral study): The PRELUDE BTK Study source ↗
Feb 1, 2017 Trial start Not phased (device or behavioral study): PRospective Study for the TrEatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator DevicE source ↗
2026-05 Trial start Not phased (device or behavioral study): Revascularization With Modification Using Definitive IVL and Serration Remodeling for Optimal Lumen source ↗
2019-09 Trial start —: Serranator® Alto Post Market Clinical Follow Up (PMCF) Study source ↗

Funding

Raised: $41.0M. Last 2 years.

Jul 15, 2026 Private equity round — Series D: $41M (total, as published), announced Jul 15, 2026. Source: company's own press page. source ↗ · Form D filed Jun 5, 2026 SEC Form D ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT07575568	Revascularization With Modification Using Definitive IVL and Serration Remodeling for Optimal Lumen	Not phased (device or behavioral study)	Not yet recruiting	2026-05	2026-08 (estimated)
NCT06687590	Serranator POINT FORCE Registry	Not listed	Recruiting	Jan 22, 2025	Jun 30, 2026 (estimated)
NCT06434194	Serrantor OCT Study	Not phased (device or behavioral study)	Recruiting	Oct 31, 2024	Jun 1, 2025 (estimated)
NCT05161039	Serranator Recoil Study	Not phased (device or behavioral study)	Unknown status (ClinicalTrials.gov)	Nov 15, 2021	2022-07 (estimated)
NCT03693963	The PRELUDE BTK Study	Not phased (device or behavioral study)	Completed	Dec 17, 2019	Apr 11, 2020 (actual)
NCT03538392	Serranator® Alto Post Market Clinical Follow Up (PMCF) Study	Not listed	Withdrawn	2019-09	2019-12 (estimated)
NCT03001700	PRospective Study for the TrEatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator DevicE	Not phased (device or behavioral study)	Completed	Feb 1, 2017	May 31, 2017 (actual)